West Pharma (WST) Tops Q2 EPS by 1c; Lowers Top End of EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
West Announces Second-Quarter 2017 Results
July 27, 2017 6:00 AM EDTEXTON, Pa., July 27, 2017 /PRNewswire/ --Â West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2017 and updated financial guidance for the full-year 2017.
Second-Quarter 2017 Highlights
Reported net sales of $397.6 million, a record high, grew 2.5% over the prior-year quarter. Net sales at constant currency (organic) grew by 3.9%. Second-quarter 2017 reported-diluted EPS was $0.51, compared to $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS was $0.66, compared to $0.59 in the prior-year quarter. Second-quarter 2017 reported and adjusted-diluted EPS include the impact... More